PROMOTION Registry | Promotion Database Content
page-template,page-template-full_width,page-template-full_width-php,page,page-id-15585,ajax_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-7.8,wpb-js-composer js-comp-ver-4.8.1,vc_responsive


Characteristics of Clinical Trials included in the Registry

  1. Randomized Controlled Clinical trials
  2. Enrolling at least 50 patients overall
  3. Having included a Patient-Reported Outcome (PRO) component
  4. Published since January 2004

Evidence Acquisition

Published papers meeting the above reported criteria are mainly searched through the following electronic databases: PubMed/Medline and the Cochrane library.

Methods of evaluation of studies

After having verified eligibility of articles, at least two reviewers (i.e., study collaborators) independently review and extract several information. Each reviewer has a personal password to access the online system and can complete the electronic-data extraction form (eDEF). This approach allows a double blind data entry procedure to ensure the highest possible quality data collection in the PROMOTION Registry. Discrepancies in the two evaluations are recorded and a discrepancy Form is electronically generated by the data collection system. On the basis of this discrepancy Form the two reviewers discuss each issue by revisiting the paper to reconcile any differences. When consensus is achieved on each single variable, a final eDEF (for that specific article) is then locked, validated and imputed in the PROMOTION database.

Type of information included for each study

More than 50 different information (i.e., variables) are included in the eDEF. Data extracted for each RCT includes:

1. Basic trial demographics and clinical and PRO characteristics (e.g., number of patients enrolled, study location, treatments being compared, PRO instrument used, clinical and PRO assessments);


2. Level of PRO reporting, based on the recently published recommendations by the International Society for Quality of Life Research (ISOQOL) (Brundage M, et al, Qual Life Res, 22: 1161-1175, 2013) and the CONSORT PRO recommendations (Calvert M, et al, JAMA, 309: 814-822, 2013);


3. Bias, assessed using the Cochrane Risk of Bias tool which rates RCTs for their adequacy of sequence generation, allocation concealment, blinding of participant/personnel, incomplete outcome data, blinding of outcome assessment, selective outcome reporting and other possible source of bias (Higgins JP, et al, BMJ 2011; 343: d5928).

Lastly, a summary of clinical and PRO data is also extracted from each paper reviewed.

Cancer Disease sites included in the Registry

To date (January 2021) 928 studies have been included in the Registry.


See more details hereunder:

Cancer Disease sites Published Until Nr. of RCTs
Breast February 2019 187
Lung (Non-Small Cell Lung) February 2019 131
Prostate February 2019 120
Colorectal/anal February 2019 107
Gynecological February 2019 86
Bladder February 2019 18
Leukemia/Lymphoma/MDS* January 2019 81
Multiple Myeloma January 2021 26
Head & Neck June 2015 66
Esophago-gastric February 2013 29
Pancreas March 2013 24
Brain June 2013 14
Kidney June 2013 13
Melanoma September 2013 10
Liver primary March 2013 9
Sarcoma August 2013 5
Testicular May 2012 3
*Myelodysplastic syndromes